C. Specific Aim III: Determine if OX25 strategy will result in lower incidence of adverse clinical outcomes compared to OX50 or OX75 strategy. Investigators hypothesize that OX25 neonates will have lower incidence of BPD. Investigators will also record other clinical outcomes such as ROP, NEC, IVH, length of hospitalization, neurodevelopmental impairment and mortality.